These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 7769903

  • 1. Replacement therapy with imiglucerase for type 1 Gaucher's disease.
    Zimran A, Elstein D, Levy-Lahad E, Zevin S, Hadas-Halpern I, Bar-Ziv Y, Foldes J, Schwartz AJ, Abrahamov A.
    Lancet; 1995 Jun 10; 345(8963):1479-80. PubMed ID: 7769903
    [Abstract] [Full Text] [Related]

  • 2. Individualised low-dose alglucerase therapy for type 1 Gaucher's disease.
    Hollak CE, Aerts JM, Goudsmit R, Phoa SS, Ek M, van Weely S, von dem Borne AE, van Oers MH.
    Lancet; 1995 Jun 10; 345(8963):1474-8. PubMed ID: 7769902
    [Abstract] [Full Text] [Related]

  • 3. Imiglucerase and its use for the treatment of Gaucher's disease.
    Weinreb NJ.
    Expert Opin Pharmacother; 2008 Aug 10; 9(11):1987-2000. PubMed ID: 18627336
    [Abstract] [Full Text] [Related]

  • 4. A less costly regimen of alglucerase to treat Gaucher's disease.
    Figueroa ML, Rosenbloom BE, Kay AC, Garver P, Thurston DW, Koziol JA, Gelbart T, Beutler E.
    N Engl J Med; 1992 Dec 03; 327(23):1632-6. PubMed ID: 1435900
    [Abstract] [Full Text] [Related]

  • 5. First long-term results of imiglucerase therapy of type 1 Gaucher disease.
    Niederau C, vom Dahl S, Häussinger D.
    Eur J Med Res; 1998 Feb 21; 3(1-2):25-30. PubMed ID: 9512964
    [Abstract] [Full Text] [Related]

  • 6. Alglucerase. A review of its therapeutic use in Gaucher's disease.
    Whittington R, Goa KL.
    Drugs; 1992 Jul 21; 44(1):72-93. PubMed ID: 1379912
    [Abstract] [Full Text] [Related]

  • 7. Imiglucerase low-dose therapy for paediatric Gaucher disease--a long-term cohort study.
    Heitner R, Arndt S, Levin JB.
    S Afr Med J; 2004 Aug 21; 94(8):647-51. PubMed ID: 15352589
    [Abstract] [Full Text] [Related]

  • 8. Imiglucerase treatment in Gaucher's disease.
    Shah U, Nadeem N, Husen Y, Fadoo Z.
    J Ayub Med Coll Abbottabad; 2007 Aug 21; 19(2):56-9. PubMed ID: 18183722
    [Abstract] [Full Text] [Related]

  • 9. [A retrospective study on enzyme replacement therapy in patients with Gaucher disease].
    Duan YL, Zhang YH, Zang Y, Shi HP, Zhang WM, Hu YM.
    Zhonghua Er Ke Za Zhi; 2006 Sep 21; 44(9):653-6. PubMed ID: 17217655
    [Abstract] [Full Text] [Related]

  • 10. Gaucher's disease: a review.
    Morales LE.
    Ann Pharmacother; 1996 Apr 21; 30(4):381-8. PubMed ID: 8729893
    [Abstract] [Full Text] [Related]

  • 11. Low-dose enzyme replacement therapy for Gaucher's disease: effects of age, sex, genotype, and clinical features on response to treatment.
    Zimran A, Elstein D, Kannai R, Zevin S, Hadas-Halpern I, Levy-Lahad E, Cohen Y, Horowitz M, Abrahamov A.
    Am J Med; 1994 Jul 21; 97(1):3-13. PubMed ID: 8030654
    [Abstract] [Full Text] [Related]

  • 12. Miglustat: new drug. In type 1 Gaucher's disease : a slight benefit after imiglucerase therapy.
    Prescrire Int; 2005 Oct 21; 14(79):168-70. PubMed ID: 16285070
    [Abstract] [Full Text] [Related]

  • 13. Enzyme replacement therapy for Gaucher's disease.
    Beutler E.
    Baillieres Clin Haematol; 1997 Dec 21; 10(4):751-63. PubMed ID: 9497862
    [Abstract] [Full Text] [Related]

  • 14. Low-dose low-frequency imiglucerase as a starting regimen of enzyme replacement therapy for patients with type I Gaucher disease.
    Elstein D, Abrahamov A, Hadas-Halpern I, Meyer A, Zimran A.
    QJM; 1998 Jul 21; 91(7):483-8. PubMed ID: 9797931
    [Abstract] [Full Text] [Related]

  • 15. Velaglucerase alfa for the management of type 1 Gaucher disease.
    Morris JL.
    Clin Ther; 2012 Feb 21; 34(2):259-71. PubMed ID: 22264444
    [Abstract] [Full Text] [Related]

  • 16. Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial.
    Cox TM, Drelichman G, Cravo R, Balwani M, Burrow TA, Martins AM, Lukina E, Rosenbloom B, Ross L, Angell J, Puga AC.
    Lancet; 2015 Jun 13; 385(9985):2355-62. PubMed ID: 25819691
    [Abstract] [Full Text] [Related]

  • 17. A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patients with Gaucher disease type 1.
    Kishnani PS, DiRocco M, Kaplan P, Mehta A, Pastores GM, Smith SE, Puga AC, Lemay RM, Weinreb NJ.
    Mol Genet Metab; 2009 Apr 13; 96(4):164-70. PubMed ID: 19195916
    [Abstract] [Full Text] [Related]

  • 18. [Alglucerase treatment of type I Gaucher's disease. Preliminary results in Spain. Spanish Group on Gaucher's Disease].
    Pérez-Calvo JI, Giraldo P, Giralt M.
    Sangre (Barc); 1997 Jun 13; 42(3):189-94. PubMed ID: 9381260
    [Abstract] [Full Text] [Related]

  • 19. Extended interval between enzyme therapy infusions for adult patients with Gaucher's disease type 1.
    Pérez-Calvo J, Giraldo P, Pastores GM, Fernández-Galán M, Martín-Nuñez G, Pocoví M.
    J Postgrad Med; 2003 Jun 13; 49(2):127-31. PubMed ID: 12867687
    [Abstract] [Full Text] [Related]

  • 20. Anaphylactoid reaction to imiglucerase, but not to alglucerase, in a type I Gaucher patient.
    Aviner S, Levy Y, Yaniv I, Cohen IJ.
    Blood Cells Mol Dis; 1999 Apr 13; 25(2):92-4. PubMed ID: 10389590
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.